Hypothesis: Intrarenal hematopoietic progenitor persistence will predict lupus nephritis nonresponse better than baseline histologic class alone

Claim

In proliferative lupus nephritis, the presence or persistence of intrarenal hematopoietic stem/progenitor-cell (HSPC) signatures after induction therapy will predict 6- to 12-month renal nonresponse better than baseline ISN/RPS histologic class alone.

Why this is plausible

A major limitation of current lupus nephritis risk stratification is that baseline class captures structure but not the dynamic inflammatory engine inside the kidney. New mechanistic work suggests that kidneys with lupus nephritis can host local hematopoietic progenitors with myeloid differentiation capacity, implying active intrarenal fuel for inflammation rather than passive leukocyte accumulation. If that biology persists despite treatment, it should mark a kidney that remains immunologically self-sustaining and therefore harder to bring into durable remission.

Testable prediction

Across prospective biopsy-linked lupus nephritis cohorts:

1. baseline intrarenal HSPC/myeloid-program abundance will associate with lower complete renal response at 6 and 12 months,
2. persistence of this signature on repeat biopsy or single-cell/spatial profiling will outperform ISN/RPS class alone for forecasting nonresponse,
3. adding the signature to standard clinicopathologic models will improve calibration and decision-curve net benefit.

Suggested study design

• Population: adults with biopsy-proven proliferative lupus nephritis starting induction therapy
• Exposure: quantified intrarenal HSPC/myeloid signature from single-cell, spatial transcriptomic, or targeted multiplex assays
• Primary outcome: complete or partial renal response at 6 and 12 months
• Comparator: baseline histologic class/activity-chronicity indices alone
• Analysis: hierarchical prediction model with internal-external cross-validation and net-benefit analysis

Falsification

This hypothesis is weakened if intrarenal HSPC signatures disappear rapidly with therapy and add no incremental predictive value beyond proteinuria, eGFR, chronicity index, and baseline class.

References

1. Yi H, Jung S, Joo JH, et al. Kidney Hematopoietic Stem and Progenitor Cells Contribute to Myeloid Development and Pathology in Lupus Nephritis. DOI: 10.1002/art.70201
2. Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis. DOI: 10.1038/s41590-019-0398-x